Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F21%3A10435194" target="_blank" >RIV/00216208:11140/21:10435194 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00669806:_____/21:10435194 RIV/00064190:_____/21:N0000020 RIV/00216208:11110/21:10435194
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=dH3oW8BbSH" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=dH3oW8BbSH</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/bmm-2021-0168" target="_blank" >10.2217/bmm-2021-0168</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients
Popis výsledku v původním jazyce
Aim: We explored whether matrix Gla protein (MGP, natural calcification inhibitor) and sclerostin (glycoprotein responsible for osteoblast differentiation) interact in terms of mortality risk in coronary patients. Methods: 945 patients after myocardial infarction and/or coronary revascularization were followed in a prospective study. All-cause death, fatal or nonfatal cardiovascular events and heart failure hospitalizations were registered. Results: Either high desphospho-uncarboxylated MGP (dp-ucMGP) or high sclerostin were independently associated with 5-year all-cause/cardiovascular mortality. However, we observed an additional mortality risk in the coincidence of both factors. Concomitantly high dp-ucMGP (>= 884 pmol/l) plus sclerostin (>= 589 ng/l) were associated with increased all-cause mortality risk compared with 'normal' concentrations of both factors (HRR 3.71 [95% CI: 2.07-6.62, p < 0.0001]), or if only one biomarker has been increased. A similar pattern was observed for fatal, but not for nonfatal cardiovascular events. Conclusion: Concomitantly high MGP and sclerostin indicate increased mortality risk, which probably reflects their role in cardiovascular calcifications.
Název v anglickém jazyce
Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients
Popis výsledku anglicky
Aim: We explored whether matrix Gla protein (MGP, natural calcification inhibitor) and sclerostin (glycoprotein responsible for osteoblast differentiation) interact in terms of mortality risk in coronary patients. Methods: 945 patients after myocardial infarction and/or coronary revascularization were followed in a prospective study. All-cause death, fatal or nonfatal cardiovascular events and heart failure hospitalizations were registered. Results: Either high desphospho-uncarboxylated MGP (dp-ucMGP) or high sclerostin were independently associated with 5-year all-cause/cardiovascular mortality. However, we observed an additional mortality risk in the coincidence of both factors. Concomitantly high dp-ucMGP (>= 884 pmol/l) plus sclerostin (>= 589 ng/l) were associated with increased all-cause mortality risk compared with 'normal' concentrations of both factors (HRR 3.71 [95% CI: 2.07-6.62, p < 0.0001]), or if only one biomarker has been increased. A similar pattern was observed for fatal, but not for nonfatal cardiovascular events. Conclusion: Concomitantly high MGP and sclerostin indicate increased mortality risk, which probably reflects their role in cardiovascular calcifications.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30201 - Cardiac and Cardiovascular systems
Návaznosti výsledku
Projekt
<a href="/cs/project/NV17-29520A" target="_blank" >NV17-29520A: Dlouhodobé trendy sekundární prevence ICHS a predikce rizika ve vybraném vzorku české populace - česká část studie EURASPIRE V</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2021
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Biomarkers in Medicine
ISSN
1752-0363
e-ISSN
—
Svazek periodika
15
Číslo periodika v rámci svazku
16
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
13
Strana od-do
1465-1477
Kód UT WoS článku
000708973300001
EID výsledku v databázi Scopus
2-s2.0-85119173049